Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) Short Interest Update

Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) was the recipient of a significant decrease in short interest in January. As of January 30th, there was short interest totaling 693,745 shares, a decrease of 97.6% from the January 15th total of 29,166,975 shares. Approximately 34.8% of the company’s stock are sold short. Based on an average daily volume of 1,796,547 shares, the days-to-cover ratio is presently 0.4 days. Based on an average daily volume of 1,796,547 shares, the days-to-cover ratio is presently 0.4 days. Approximately 34.8% of the company’s stock are sold short.

Institutional Investors Weigh In On Aspire Biopharma

Several large investors have recently made changes to their positions in ASBP. CIBC Bancorp USA Inc. acquired a new position in shares of Aspire Biopharma during the 3rd quarter worth $28,000. Jane Street Group LLC boosted its holdings in Aspire Biopharma by 625.8% in the second quarter. Jane Street Group LLC now owns 152,552 shares of the company’s stock worth $41,000 after purchasing an additional 131,533 shares in the last quarter. Optivise Advisory Services LLC increased its position in Aspire Biopharma by 120.9% during the second quarter. Optivise Advisory Services LLC now owns 235,106 shares of the company’s stock worth $63,000 after buying an additional 128,660 shares during the last quarter. Finally, Crewe Advisors LLC raised its holdings in Aspire Biopharma by 100.0% during the second quarter. Crewe Advisors LLC now owns 626,854 shares of the company’s stock valued at $169,000 after buying an additional 313,427 shares in the last quarter. Institutional investors own 19.17% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on ASBP shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aspire Biopharma in a report on Wednesday, January 21st. Wall Street Zen raised shares of Aspire Biopharma to a “sell” rating in a report on Saturday, January 17th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Aspire Biopharma Price Performance

Aspire Biopharma stock traded down $0.03 during mid-day trading on Tuesday, hitting $1.41. The company’s stock had a trading volume of 346,054 shares, compared to its average volume of 1,555,450. Aspire Biopharma has a 52-week low of $1.26 and a 52-week high of $632.00. The company has a market cap of $3.79 million, a PE ratio of -0.07 and a beta of 0.82. The firm’s 50 day moving average is $3.21 and its 200 day moving average is $10.22.

Aspire Biopharma (NASDAQ:ASBP) last posted its quarterly earnings results on Friday, November 14th. The company reported ($1.60) earnings per share (EPS) for the quarter. The firm had revenue of $0.00 million for the quarter.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.